ValuEngine Upgrades Noodles & Company To STRONG BUY

For today's edition of our upgrade list, we used our website's advanced screening functions to search for UPGRADES to BUY or STRONG BUY with complete forecast and valuation data. They are presented by one-month forecast return. Hanwha Q-Cells, Blueprint Medicines, and Noodles and Co. are rated STRONG BUY. GOL-Linhas and Heritage Crystal are rated BUY.

Ticker	Company Name	Market Price	Valuation	Last 12-M Return	1-M Forecast Return	1-Yr Forecast Return	P/E Ratio	Sector Name
HQCL	HANWHA Q CELLS	9.7	56.59%	25.97%	1.15%	13.83%	N/A	Computer and Technology
BPMC	BLUEPRINT MED	72.07	86.09%	12.33%	1.11%	13.30%	N/A	Medical
NDLS	NOODLES & CO	13.23	28.47%	198.98%	1.09%	13.09%	661.50	Retail-Wholesale
GOL	GOL LINHAS-ADR	8.61	52.89%	-5.76%	0.60%	7.25%	29.69	Transportation
HCCI	HERITAGE-CRYSTL	22.02	15.62%	3.14%	0.60%	7.14%	36.70	Industrial Products

Today, we take a look at Noodles & Company (NDLS). Noodles & Company is a fast casual restaurant which offers lunch and dinner. It serves noodles, pastas, salads, soups, sandwiches, cheese, meatballs and beverages. The company operates in the United States. Noodles & Company is based in Broomfield, Colorado.

This stock has caught fire lately due to some timely analyst upgrades and a new product that many think will give the company an edge. Noodles is riding the low-carb and paleo craze by providing customers and alternative to high-carb traditional pastas. Many analysts think the company's zucchini noodles--known as "zoodles"--will help differentiate the restaurants and make consumers take notice.

ValuEngine updated its recommendation from BUY to STRONG BUY for NOODLES & CO on 2018-10-16. Based on the information we have gathered and our resulting research, we feel that NOODLES & CO has the probability to OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE Momentum and Earnings Growth Rate.

ValuEngine Forecast
	Target Price*	Expected Return
1-Month	13.37	1.09%
3-Month	13.54	2.33%
6-Month	13.97	5.62%
1-Year	14.96	13.09%
2-Year	14.77	11.61%
3-Year	14.60	10.36%

Valuation & Rankings
Valuation	28.47% overvalued	Valuation Rank(?)	13
1-M Forecast Return	1.09%	1-M Forecast Return Rank	99
12-M Return	198.98%	Momentum Rank(?)	99
Sharpe Ratio	-0.45	Sharpe Ratio Rank(?)	19
5-Y Avg Annual Return	-25.29%	5-Y Avg Annual Rtn Rank	18
Volatility	56.79%	Volatility Rank(?)	28
Expected EPS Growth	650.00%	EPS Growth Rank(?)	98
Market Cap (billions)	0.37	Size Rank	48
Trailing P/E Ratio	661.50	Trailing P/E Rank(?)	30
Forward P/E Ratio	88.20	Forward P/E Ratio Rank	4
PEG Ratio	1.02	PEG Ratio Rank	39
Price/Sales	0.82	Price/Sales Rank(?)	73
Market/Book	20.38	Market/Book Rank(?)	8
Beta	-0.54	Beta Rank	91
Alpha	1.09	Alpha Rank	99